Get the Stockscreener App
4.05
1.76%
0.07
After Hours:
3.97
-0.08
-1.98%
Plus Therapeutics Inc stock is traded at $4.05, with a volume of 165.70K.
It is up +1.76% in the last 24 hours and down -25.14% over the past month.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, commercializing and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).
See More
Previous Close:
$3.98
Open:
$3.96
24h Volume:
165.70K
Relative Volume:
0.15
Market Cap:
$27.88M
Revenue:
$5.21M
Net Income/Loss:
$-26.35M
P/E Ratio:
-0.1262
EPS:
-32.0862
Net Cash Flow:
$-20.84M
1W Performance:
-5.59%
1M Performance:
-25.14%
6M Performance:
+621.93%
1Y Performance:
+1,266%
1-Day Range:
$3.825
$4.10
1-Week Range:
$3.825
$4.51
52-Week Range:
$0.129
$8.00
Plus Therapeutics Inc Stock (PSTV) Company Profile
Name
Plus Therapeutics Inc
Sector
Industry
Phone
737.255.7194
Address
4200 MARATHON BLVD., AUSTIN, TX
Compare PSTV vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PSTV
Plus Therapeutics Inc
|
4.05 | 30.08M | 5.21M | -26.35M | -20.84M | -32.09 |
VRTX
Vertex Pharmaceuticals Inc
|
529.59 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.81 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.80 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.04 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.99 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Plus Therapeutics Inc Stock (PSTV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-03-26 | Initiated | Lake Street | Buy |
| Sep-03-25 | Upgrade | D. Boral Capital | Hold → Buy |
| Mar-17-25 | Initiated | D. Boral Capital | Buy |
| Jan-25-21 | Initiated | Ladenburg Thalmann | Buy |
| Oct-16-20 | Initiated | Maxim Group | Buy |
Plus Therapeutics Inc Stock (PSTV) Latest News
Plus Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Hawkins Richard J - Moomoo
Plus Therapeutics (PSTV) CEO gains 16,439 shares from RSU vesting - Stock Titan
PLUS Therapeutics (PSTV) director converts 922 RSUs into common stock - Stock Titan
Plus Therapeutics (NASDAQ: PSTV) director gains 922 shares via RSU vesting - Stock Titan
PLUS Therapeutics (PSTV) CFO converts RSUs into 2,985 common shares - Stock Titan
[Form 4] PLUS THERAPEUTICS, INC. Insider Trading Activity - Stock Titan
Plus Therapeutics provides mid-year business update including corporate rebranding - MSN
Plus Therapeutics Advances REYOBIQ Clinical Trials and Manufacturing Progress - marketscreener.com
Plus Therapeutics to rebrand as Cerenome and adopt CNSY ticker on August 3 (PSTV) - Yahoo Finance
Plus Therapeutics to rebrand as Cerenome, change ticker to CNSY - Investing.com
From Plus to Cerenome: A New Identity for an Integrated CNS Cancer Strategy - BriefGlance
Price to earnings forward of PLUS THERAPEUTICS, Inc. – NASDAQ:PSTV - TradingView
Price to sales forward of PLUS THERAPEUTICS, Inc. – NASDAQ:PSTV - TradingView
Enterprise value to revenue forward of PLUS THERAPEUTICS, Inc. – NASDAQ:PSTV - TradingView
Plus Therapeutics, Inc.(NasdaqCM: PSTV) added to Russell 3000E Index - marketscreener.com
Plus Therapeutics, Inc.(NasdaqCM: PSTV) added to Russell 3000E Growth Benchmark - marketscreener.com
Plus Therapeutics, Inc.(NasdaqCM: PSTV) added to Russell Microcap Index - marketscreener.com
Plus Therapeutics, Inc. Actuals & Estimates (DUS:XMP1) - TradingView
XMP1 Forecast — Price Target — Prediction for 2027 - TradingView
Plus Therapeutics, Inc. Actuals & Estimates (GETTEX:XMP1) - TradingView
Plus Therapeutics, Inc. Actuals & Estimates (FWB:XMP1) - TradingView
Plus Therapeutics, Inc. Actuals & Estimates (NASDAQ:PSTV) - TradingView
CNSide signs coverage deal with Elevance Health for 45.4M - Investing.com UK
Plus Therapeutics wins Elevance Health coverage deal - MSN
PSTV Forecast — Price Target — Prediction for 2027 - TradingView
Plus Therapeutics Secures National Coverage Agreement with Elevance Health for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer - The Manila Times
Plus Therapeutics Subsidiary CNSide Diagnostics Signs National Coverage Agreement with Elevance Health for CNSide CSF Tumor Cell Enumeration Assay - Quiver Quantitative
Plus Therapeutics Secures National Coverage Agreement with - GlobeNewswire
Plus Therapeutics (PSTV) reports Q1 loss, tops revenue estimates - MSN
Plus Therapeutics to Provide Business Update Call on June 30, 2026 - Sahm
Plus Therapeutics to detail CNSide launch, Reyobiq plan June 30 - Stock Titan
Plus Therapeutics Inc (PSTV) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
PSTV Should I Buy - Intellectia AI
Plus Therapeutics Inc (PSTV) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Plus Therapeutics Inc (PSTV) Valuation: PE, PB & Fair Value Analysis - TradingKey
Plus Therapeutics Inc (PSTV) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Plus Therapeutics Inc (PSTV) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Plus Therapeutics Inc (PSTV) Institutional Confidence - TradingKey
Plus Therapeutics Inc (PSTV) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Plus Therapeutics Inc (PSTV) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Plus Therapeutics Inc Annual Shareholders Meeting Transcript - GuruFocus
Plus Therapeutics Is Maintained at Buy by Ascendiant Capital - Moomoo
PSTV Maintained by Ascendiant Capital -- Price Target Lowered to $57.00 - GuruFocus
[EFFECT] PLUS THERAPEUTICS, INC. SEC Filing - Stock Titan
Plus Therapeutics Launches New At-The-Market Equity Program - The Globe and Mail
PLUS THERAPEUTICS, INC. Files Form 8-K with SEC Detailing Material Definitive Agreement – June 2026 - Minichart
Plus Therapeutics Launches $17.35 Million ATM Equity Program With Canaccord Genuity - TradingView
Plus Therapeutics (NASDAQ: PSTV) sets $17,350,000 at-the-market stock program - Stock Titan
Plus Therapeutics (PSTV) adds Form of Indenture to S-3/A filing - Stock Titan
Plus Therapeutics gains CAP accreditation for CNSide CSF assay platform - Yahoo Finance
CNSide Diagnostics receives laboratory accreditation from CAP By Investing.com - Investing.com Nigeria
Plus Therapeutics Inc Stock (PSTV) Financials Data
Revenue
Net Income
Cash Flow
EPS
Plus Therapeutics Inc Stock (PSTV) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| ANDREWS RONALD ASBURY | Director |
Jul 01 '26 |
Option Exercise |
0.00 |
922 |
0 |
922 |
| van Es-Johansson An | Director |
Jul 01 '26 |
Option Exercise |
0.00 |
922 |
0 |
922 |
| HEDRICK MARC H | Chief Executive Officer |
Jul 01 '26 |
Option Exercise |
0.00 |
16,439 |
0 |
44,483 |
| Clowes Howard | Director |
Jul 01 '26 |
Option Exercise |
0.00 |
922 |
0 |
1,981 |
| Hawkins Richard J | Director |
Jul 01 '26 |
Option Exercise |
0.00 |
922 |
0 |
1,529 |
| Sims Andrew John Hugh MacIntyr | Chief Financial Officer |
Jul 01 '26 |
Option Exercise |
0.00 |
2,985 |
0 |
9,941 |
| Sims Andrew John Hugh MacIntyr | Chief Financial Officer |
Apr 01 '26 |
Option Exercise |
0.00 |
67,452 |
0 |
173,913 |
| HEDRICK MARC H | Chief Executive Officer |
Apr 01 '26 |
Option Exercise |
0.00 |
159,681 |
0 |
499,468 |
| HEDRICK MARC H | Chief Executive Officer |
Jan 01 '26 |
Option Exercise |
0.00 |
159,681 |
0 |
339,787 |
| Sims Andrew John Hugh MacIntyr | Chief Financial Officer |
Jan 01 '26 |
Option Exercise |
0.00 |
38,323 |
0 |
106,461 |
0.05%
0.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):